Company intelligence / Profile preview

Climb On Equipment

San Francisco, CA, USA

Ownership: Private
Development stage: Other

Overview

Climb Bio is a clinical-stage biotechnology company dedicated to developing precision therapies for rare childhood-onset epilepsies. The company utilizes a proprietary zebrafish-based phenotypic screening platform to identify small molecules that modulate serotonin signaling to reduce seizure activity. Its lead candidate, EPX-100 (clemizole hydrochloride), is currently in Phase 2 clinical trials for the treatment of Dravet syndrome. By repurposing and optimizing existing compounds, Climb Bio aims to provide safer and more effective treatment options for patients with severe, treatment-resistant seizure disorders.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Climb On Equipment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Climb On Equipment.

Explore the full profile